Your browser doesn't support javascript.
Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center.
Fernandes, Gisele Aparecida; Feriani, Diego; França E Silva, Ivan Leonardo Avelino; Mendonça E Silva, Diego Rodrigues; Arantes, Paola Engelmann; Canteras, Juliana da Silva; da Silva, Rodrigo Reghini; Curado, Maria Paula.
  • Fernandes GA; Group of Epidemiology and Statistics on Cancer, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Feriani D; Department of Infection Prevention and Control, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • França E Silva ILA; Department of Infection Prevention and Control, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Mendonça E Silva DR; Group of Epidemiology and Statistics on Cancer, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Arantes PE; Group of Epidemiology and Statistics on Cancer, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Canteras JDS; Department of Infection Prevention and Control, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • da Silva RR; Department of Infection Prevention and Control, AC Camargo Cancer Center, São Paulo, SP, Brazil.
  • Curado MP; Group of Epidemiology and Statistics on Cancer, AC Camargo Cancer Center, São Paulo, SP, Brazil. Electronic address: mp.curado@accamargo.org.br.
Semin Oncol ; 48(2): 171-180, 2021 04.
Article in English | MEDLINE | ID: covidwho-1057723
ABSTRACT

INTRODUCTION:

To analyze COVID-19 mortality in cancer patients and associated factors such as age, sex, type of insurance, situation at COVID-19 diagnosis, and cancer histology during the pandemic at a cancer center in Brazil.

METHODS:

Cross-sectional study carried out from April 02, 2020 to August 31, 2020 at A.C. Camargo Cancer Center (ACCCC), in São Paulo, Brazil. Cases were extracted from the Hospital Cancer Registry. COVID-19 lethality rates by histology were calculated; multiple logistic regression was used to identify factors associated with COVID-19 mortality. The log-rank test was applied to compare the survival curves for each variable.

RESULTS:

Of the 411 patients analyzed, 51 (12.4%) died due to COVID-19. Death occurred at an average age of 63 years. The fatality rate was higher for lung (0.333) and hematological (0.213) cancers and was associated with age over 60 years. The greatest chances of death from COVID-19 were in cases of lung (odds ratio, OR, 4.05, 95% confidence interval, CI 1.33-12.34) and hematological (OR 2.17, 95% CI 0.96-4.90) cancers, and in patients currently undergoing cancer treatment (OR 2.77, 95% CI 1.25-6.13). There were no statistical differences in survival by sex, age group, type of insurance, situation at the diagnosis of COVID-19, and histology of cancer for COVID-19.

CONCLUSIONS:

Mortality due to COVID-19 in cancer patients is heterogeneous. These findings reinforce the need for individualized strategies for the management of different types of cancer that reduce the risk of death from COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Female / Humans / Male / Middle aged Country/Region as subject: South America / Brazil Language: English Journal: Semin Oncol Year: 2021 Document Type: Article Affiliation country: J.seminoncol.2021.01.003

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Female / Humans / Male / Middle aged Country/Region as subject: South America / Brazil Language: English Journal: Semin Oncol Year: 2021 Document Type: Article Affiliation country: J.seminoncol.2021.01.003